Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of blinatumomab for minimal residual disease in high-risk diffuse large B-cell lymphoma after autologous stem-cell transplantation
2016-003255-30Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL), sponsored by Amgen. Started Jul 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2016-003255-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003255-30.